Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530
SL Locatelli, G Careddu, S Serio, FM Consonni… - Clinical Cancer …, 2019 - AACR
Purpose: Tumor-associated macrophages (TAMs) and the hyperactivation of the PI3K/AKT
pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome. …
pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome. …
FGF trapping inhibits multiple myeloma growth through c-Myc degradation–induced mitochondrial oxidative stress
…, GC Ghedini, F Maccarinelli, A Sacco, SL Locatelli… - Cancer research, 2020 - AACR
… KMS-11 and t(4;14)-negative RPMI8226 cells after treatment with NSC12 6 μmol/L. D,
Western blot analysis of KMS-11 and RPMI8226 cells after treatment with NSC12 6 μmol/L. …
Western blot analysis of KMS-11 and RPMI8226 cells after treatment with NSC12 6 μmol/L. …
[HTML][HTML] Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy
M Pierdominici, A Maselli, SL Locatelli, L Ciarlo… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Although Hodgkin lymphoma (HL) is curable with current therapy, at least 20% of patients
relapse or fail to make complete remission. In addition, patients who achieve long-term disease…
relapse or fail to make complete remission. In addition, patients who achieve long-term disease…
A first-in-human study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: Results from the European study
…, L Scarfo, PJ Barde, A Nair, SL Locatelli… - … Myeloma and Leukemia, 2020 - Elsevier
… Adequate organ system function were defined as haemoglobin ≥ 8 g/dL, absolute neutrophil
count (ANC) ≥ 0.75 × 10 9 /L, platelets ≥ 50 × 10 9 /L, total bilirubin ≤ 1.5 times the upper …
count (ANC) ≥ 0.75 × 10 9 /L, platelets ≥ 50 × 10 9 /L, total bilirubin ≤ 1.5 times the upper …
YM155 sensitizes triple‐negative breast cancer to membrane‐bound TRAIL through p38 MAPK‐and CHOP‐mediated DR5 upregulation
…, M De Cesare, A Lopergolo, SL Locatelli… - … Journal of Cancer, 2015 - Wiley Online Library
Because available treatments have limited efficacy in triple‐negative breast cancer (TNBC),
the identification of new therapeutic strategies to improve patients' outcome is urgently …
the identification of new therapeutic strategies to improve patients' outcome is urgently …
Phase II study of sorafenib in patients with relapsed or refractory lymphoma
A Guidetti, C Carlo‐Stella, SL Locatelli… - British journal of …, 2012 - Wiley Online Library
The safety and activity of the multikinase inhibitor sorafenib were investigated in patients with
relapsed or refractory lymphoproliferative disorders who received sorafenib (400 mg) twice …
relapsed or refractory lymphoproliferative disorders who received sorafenib (400 mg) twice …
[HTML][HTML] Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells
The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib
were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, …
were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, …
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases
A Guidetti, C Carlo-Stella, SL Locatelli, W Malorni… - Clinical Cancer …, 2014 - AACR
Purpose: To evaluate safety and activity of perifosine and sorafenib combination therapy in
patients with lymphoproliferative diseases. Experimental Design: Patients with relapsed and …
patients with lymphoproliferative diseases. Experimental Design: Patients with relapsed and …
The natural estrogen receptor beta agonist silibinin as a promising therapeutic tool in diffuse large B-cell lymphoma
E Ortona, SL Locatelli, MT Pagano… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: About 40% of patients with diffuse large cell lymphoma (DLBCL) still have
a poor prognosis. Additionally, DLBCL patients treated with doxorubicin are at risk of cardiac …
a poor prognosis. Additionally, DLBCL patients treated with doxorubicin are at risk of cardiac …
Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia
…, M Ruella, R Miceli, L Devizzi, SL Locatelli… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Because the long‐term toxicity of myeloablative radioimmunotherapy remains
a matter of concern, the authors evaluated the hematopoietic damage and incidence of …
a matter of concern, the authors evaluated the hematopoietic damage and incidence of …